On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage ...

AstraZeneca achieved record revenue growth of 18% in 2024, driven by key products like Farxiga and Tagrisso, and numerous regulatory approvals. The company’s diversified portfolio spans oncology, CVRM ...

AstraZeneca plc (NASDAQ:AZN) is exploring whether one of its biggest cancer drugs can work better with a carefully selected ...

AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs. The R ...

AstraZeneca Plc (NASDAQ:AZN) on Thursday said it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing ...

AstraZeneca has launched an online direct-to-consumer (DTC) medicine platform in the US, joining a growing list of companies opting for the model in a bid to cut drug prices amid pressure from ...

AstraZeneca plc is refining its long-term pipeline and commercialization strategy to align new therapies with growing global demand for innovative medicines, amid ongoing interest in large-cap ...